Jun 22, 2023 / 05:00PM GMT
Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division - MD of Equity Research
Thank you for joining us. I am Jeff Cohen, I joined with my colleague Destiny Hance at Ladenburg Thalmann. Today, we're happy to have Lisa Conte with us. Lisa is CEO, President and Director of (inaudible) of Jaguar Health. Lisa, thanks for the time. We really appreciate it. We're not going to dive as macro into the company, Jaguar, but today is really focused around CTD specifically the Phase 3 trial and patient experience.
So Lisa I'm going to turn it over to you.
Lisa A. Conte - Jaguar Health, Inc. - Founder, CEO, President & Director
Thanks. You just want to unmute, but you already have turned it over to me. So we're good. And thank you. Thank you for the time and the opportunity to fill people in and we're so excited about what we feel will be absolutely transformative for patients and for value recognition in this company right now in this really tough, tough biotech markets.
We have completed enrollment in the study we call the OnTarget
Ladenburg Thalmann to Host Virtual Discussion with Jaguar Health Inc Transcript
Jun 22, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers